Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.32 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16877581 | 1.00 | CHEK1 (0.32) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL1117505 | 1.00 | CHEK1 (0.32) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| Hydrochloric Acid SCHEMBL5280351 | 0.97 | CHEK1 (0.31) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL27323 | 0.97 | — | — | |
| SCHEMBL25231616 | 0.93 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL16877500 | 0.93 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL34475539 | 0.93 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL20104746 | 0.93 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL21573995 | 0.93 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL25229684 | 0.93 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 842 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070278-A | Bifunctional protein degradation agent containing aryl substituted heteroaryl and application thereof | 标新生物医药科技(上海)有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-12-30 | — | — | US | claimed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-07-10 | — | — | US | claimed |
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| CN-119504695-A | Preparation method of drug intermediate azaspiro [4.5] decane derivative | 上海皓鸿生物医药科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| EP-4504730-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | Dana-Farber Cancer Institute, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| CN-119365454-A | Discovery of covalent EGFR inhibitors through cysteine 775 | 丹娜-法伯癌症研究院 | 2025-01-24 | — | — | CN | claimed |
| CN-115279747-B | FYN and VEGFR2 kinase inhibitors | 罗达制药生物技术有限责任公司 | 2024-11-05 | — | — | CN | claimed |
| CN-118812564-A | EGFR-targeting proteolytic targeting chimeras, compositions and uses thereof | 厦门宝太生物科技股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| WO-2015001076-A1 | NOVEL GAK MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-01-08 | — | — | WO | claimed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | claimed |
| EP-2611777-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL]AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | claimed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-2410854-A2 | SUBSTITUTED 1, 4-DIOXA-8-AZASPIRO Ý4,5¨DECANES USEFUL AS FUNGICIDES AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2012-02-01 | — | — | EP | claimed |
| WO-2010109299-A2 | SUBSTITUTED 1, 4-DIOXA-8-AZASPIRO [4,5] DECANES USEFUL AS FUNGICIDES AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-09-30 | — | — | WO | claimed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | claimed |
| WO-2003000058-A1 | SELECTIVE HERBICIDES BASED ON PYRIMIDINE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-01-03 | — | — | WO | claimed |
| US-6075033-A | Anthranilic acid diamides derivatives, their preparation and pharmaceutical use as anti-gastrin agents | ROTTA RESEARCH LABORATORIUM S.P.A (IT) | 2000-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | FYN, LCK, LYN | CHEK1 1748/4885AURKA 838/4885RPS6KA5 399/4885 |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | CHEK1 3775/4885AURKA 3745/4885RPS6KA5 3692/4885 |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CHEK1 3110/4885AURKA 3001/4885RPS6KA5 1711/4885 |
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | EGFR, ERBB2, ERBB3 | CHEK1 33/4885AURKA 799/4885RPS6KA5 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.